NO952171L - 3-heteroalifatyl- og 3-hetero(aryl)alifatyl-2(1H)-chinolon-derivater - Google Patents

3-heteroalifatyl- og 3-hetero(aryl)alifatyl-2(1H)-chinolon-derivater

Info

Publication number
NO952171L
NO952171L NO952171A NO952171A NO952171L NO 952171 L NO952171 L NO 952171L NO 952171 A NO952171 A NO 952171A NO 952171 A NO952171 A NO 952171A NO 952171 L NO952171 L NO 952171L
Authority
NO
Norway
Prior art keywords
optionally
amidated
cyano
unsubstituted
stands
Prior art date
Application number
NO952171A
Other languages
English (en)
Other versions
NO952171D0 (no
Inventor
Hans Allgeier
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO952171D0 publication Critical patent/NO952171D0/no
Publication of NO952171L publication Critical patent/NO952171L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

3-heteroalifatyl- og 3-hetero(aryl)alifatyl-2(lH)-chinolonderivater med~ formel I. hvor restene R, R2. R3 og Ruavhengig av hverandre står for hydrogen, alifatiske hydrokarbonrester, eventuelt foretret hydroksy, eventuelt foretret og/eller oksydert merkapto, lkke-substituert eller allfatisk substituert amino, nitro, eventuelt forestret eller amidert karboksyky, cyano, eventuelt amidert sulfamoyl, halogen eller trlfluormetyl,. X står for oksy eller eventuelt oksydert tlo,. A står for en toverdig allfatisk rest og. Rstår for en ikke-substituert eller med en allfatisk eller aralifatisk hydrokarbonrest, eventuelt foretret hydroksy, eventuelt foretret og/eller oksydert merkapto, ikke-substituert eller allfatisk substituert amlno, allfatisk acyl, eventuelt forestret eller amidert karboksy, cyano, eventuelt amidert sulfamoyl, halogen og/eller trifluormetyl substituert, eventuelt delvis hydrert aryl- eller heteroarylrest, eventuelt foretret hydroksyrnety1, cyano eller eventuelt forestret eller amidert karboksy, deres tautomerer og/eller salter, har antagonistiske egenskaper overfor ek-sikatoriske aminosyrer, og kan bli anvendt som antikon-vulsive og antineurogenerative legemiddelstoffer.
NO952171A 1994-06-02 1995-06-01 3-heteroalifatyl- og 3-hetero(aryl)alifatyl-2(1H)-chinolon-derivater NO952171L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH173294 1994-06-02

Publications (2)

Publication Number Publication Date
NO952171D0 NO952171D0 (no) 1995-06-01
NO952171L true NO952171L (no) 1995-12-04

Family

ID=4217306

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952171A NO952171L (no) 1994-06-02 1995-06-01 3-heteroalifatyl- og 3-hetero(aryl)alifatyl-2(1H)-chinolon-derivater

Country Status (15)

Country Link
US (1) US5633379A (no)
EP (1) EP0685466A1 (no)
JP (1) JPH0841027A (no)
KR (1) KR960000868A (no)
CN (1) CN1120538A (no)
AU (1) AU2033695A (no)
BR (1) BR9502647A (no)
CA (1) CA2150645A1 (no)
FI (1) FI952650A (no)
HU (1) HUT72608A (no)
IL (1) IL113975A0 (no)
NO (1) NO952171L (no)
NZ (1) NZ272258A (no)
RU (1) RU95109098A (no)
ZA (1) ZA954507B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2943725B2 (ja) 1996-01-17 1999-08-30 大日本インキ化学工業株式会社 キノリノン誘導体及びそれを有効成分とする抗アレルギー剤
DE19601782A1 (de) * 1996-01-19 1997-07-24 Merck Patent Gmbh Chinolin-2-(1H)one
DE69809827D1 (de) * 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
KR100301129B1 (ko) * 1997-11-06 2001-11-30 김충섭 3-(치환-페닐티오)-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
US6689791B2 (en) * 2002-03-01 2004-02-10 R. T. Alamo Ventures I, Llc Carboxylated heterocyclic compounds and methods of synthesis
MX2009014216A (es) * 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
CN103508950B (zh) * 2012-06-25 2016-04-20 南开大学 含亚胺结构的4-羟基-2-喹啉酮类化合物及其制备和应用
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
KR101847567B1 (ko) 2015-12-24 2018-04-10 주식회사 포스코 미세하고 균일한 도금 조직을 갖는 도금 강판

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847927A (en) * 1972-12-20 1974-11-12 Dow Chemical Co Sulfur-containing hydroxypyridones
US4124587A (en) * 1976-03-01 1978-11-07 Sandoz, Inc. 4-Hydroxy-3-sulfinyl-quinolin-2(1H)-ones
US4127574A (en) * 1976-03-01 1978-11-28 Sandoz, Inc. 4-Hydroxy-3-sulfonyl-quinolin-2(1H)-ones
EP0459561B1 (en) * 1990-05-31 1995-09-20 MERCK SHARP & DOHME LTD. Dioxo-tetrahydroquinoline derivatives
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
GB9125485D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
FI952650A0 (fi) 1995-05-31
IL113975A0 (en) 1995-10-31
KR960000868A (ko) 1996-01-25
HU9501598D0 (en) 1995-07-28
CA2150645A1 (en) 1995-12-03
NZ272258A (en) 1996-12-20
FI952650A (fi) 1995-12-03
ZA954507B (en) 1996-02-01
HUT72608A (en) 1996-05-28
BR9502647A (pt) 1996-04-23
CN1120538A (zh) 1996-04-17
US5633379A (en) 1997-05-27
RU95109098A (ru) 1997-03-10
EP0685466A1 (de) 1995-12-06
JPH0841027A (ja) 1996-02-13
AU2033695A (en) 1995-12-14
NO952171D0 (no) 1995-06-01

Similar Documents

Publication Publication Date Title
NO952171L (no) 3-heteroalifatyl- og 3-hetero(aryl)alifatyl-2(1H)-chinolon-derivater
TR200200234T2 (tr) Tirozin Protein kinaz SYK purin türevleri inhibitörleri
DK1140078T3 (da) Vaskulærskadende benzimidazolmidler
NO20002958L (no) Benzamidinderivater som koagulasjonsfaktor Xa-hemmere
MY139102A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
FI952607A0 (fi) Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi
DK1216225T3 (da) Nye aminodicarboxylsyrederivater med farmaceutiske egenskaber
DE60023870T2 (de) Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
ATE170883T1 (de) Verfahren zur zweistufigen herstellung von wässrigen, selbstvernetzenden copolymerisatdispersionen und deren verwendung für lacke
WO2002081448A1 (fr) Derive benzamidine
DE60317562D1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
YU21401A (sh) Tetrahidropiridoetri
ATE400577T1 (de) Anellierte dihydropyrane
NO954975L (no) Aromatisk substituerte w-amino-alkansyreamider og alkansyrediamider
AU5648496A (en) Pyrazolo-(1,5a)pyrimidines, their preparation and their use
TR200003200T2 (tr) Faktör XA'yı önleyen heterosiklik türevler.
DE69217071T2 (de) Wasserlösliche Vinylacetat/Maleinsäurehalbamid-Copolymere und ihre Verwendung als Verflüssiger oder Wasserreduziermittel für wässrige Dispersionen
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
WO2002028821A3 (de) Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften.
IL162314A (en) Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation, pharmaceutical compositions comprising them and uses thereof
DE60310609D1 (de) Verfahren zur herstellung von 2-aminomethylpyridin-derivaten
DE68904385D1 (de) Thioformamidine, verfahren zu deren herstellung und deren anwendung als arzneimittel.
HUP0203161A2 (hu) Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1270662A3 (de) Hydrokolloidzusammensetzung sowie deren Verwendung zur Herstellung redispergierbarer Beschichtungen, Filme, Folien oder Papiere